Search

Displaying results 2091 - 2100 of 5895 in total
  1. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    own infected B-cells, thereby helping to control this condition. … Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers.

  2. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] The treatment effect was maintained for up to 12 months.[L2933] … the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.

  3. Drug

    Guanadrel

    go.drugbank.com/drugs/DB00226
    Approved

    Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

  4. Drug

    Metamfetamine

    go.drugbank.com/drugs/DB01577
    ApprovedIllicitInvestigationalWithdrawn

    It is a scheduled drug in most countries due to its high potential for addiction and abuse.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Sertraline

    go.drugbank.com/drugs/DB01104
    ApprovedInvestigational

    Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: SERTRALINA SIGMA TAU GENERICS, SERTRALINA DOC GENERICI
  6. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. … The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.

    Products: IMATINIB DOC GENERICI
  7. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. … Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.

  8. Drug

    Trimethaphan

    go.drugbank.com/drugs/DB01116
    ApprovedInvestigational

    A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.

  9. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    This leads to the reduction of the compound muscle action potential (CMAP) [A33863]. … ) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation [F272].

  10. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. … It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three